LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Lyell Immunopharma Inc

Suletud

12.63 10.5

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.5

Max

12.69

Põhinäitajad

By Trading Economics

Sissetulek

140M

-52M

Müük

-4K

7K

Aktsiakasum

-3.6

Kasumimarginaal

-745,642.857

Töötajad

300

EBITDA

3.7M

-54M

Soovitused

By TipRanks

Soovitused

Müü

12 kuu keskmine prognoos

+25.39% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

2.4B

Eelmine avamishind

2.13

Eelmine sulgemishind

12.63

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Lyell Immunopharma Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. juuni 2025, 14:31 UTC

Tulu

New York State Retirement Fund Posts 5.84% Annual Investment Return

6. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. juuni 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. juuni 2025, 20:33 UTC

Tulu

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6. juuni 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6. juuni 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6. juuni 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6. juuni 2025, 16:35 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 16:34 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6. juuni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. juuni 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6. juuni 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6. juuni 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6. juuni 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6. juuni 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. juuni 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6. juuni 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6. juuni 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6. juuni 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6. juuni 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6. juuni 2025, 14:12 UTC

Tulu

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6. juuni 2025, 14:09 UTC

Tulu

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Lyell Immunopharma Inc Prognoos

Hinnasiht

By TipRanks

25.39% tõus

12 kuu keskmine prognoos

Keskmine 16 USD  25.39%

Kõrge 20 USD

Madal 12 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lyell Immunopharma Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

3 ratings

0

Osta

2

Hoia

1

Müü

Tehniline skoor

By Trading Central

0.4217 / 0.4691Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

No Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.